WO2010023207A2 - Antimicrobial agents - Google Patents

Antimicrobial agents Download PDF

Info

Publication number
WO2010023207A2
WO2010023207A2 PCT/EP2009/060947 EP2009060947W WO2010023207A2 WO 2010023207 A2 WO2010023207 A2 WO 2010023207A2 EP 2009060947 W EP2009060947 W EP 2009060947W WO 2010023207 A2 WO2010023207 A2 WO 2010023207A2
Authority
WO
WIPO (PCT)
Prior art keywords
endolysin
seq
amino acid
modified
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/060947
Other languages
English (en)
French (fr)
Other versions
WO2010023207A3 (en
Inventor
Yves Briers
Rob Lavigne
Guido Volckaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA201100312A priority Critical patent/EA024794B1/ru
Priority to US13/061,053 priority patent/US9809808B2/en
Priority to DK09782176.3T priority patent/DK2331687T3/da
Priority to PL09782176T priority patent/PL2331687T3/pl
Priority to JP2011524360A priority patent/JP5153943B2/ja
Priority to AU2009286760A priority patent/AU2009286760B2/en
Priority to MX2011001957A priority patent/MX2011001957A/es
Priority to CN200980142373.XA priority patent/CN102197132B/zh
Priority to ES09782176T priority patent/ES2395357T3/es
Priority to CA2735077A priority patent/CA2735077C/en
Priority to EP09782176A priority patent/EP2331687B1/en
Priority to KR1020117006983A priority patent/KR101473271B1/ko
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Priority to BRPI0917508-3A priority patent/BRPI0917508A2/pt
Priority to HK11112268.7A priority patent/HK1157818B/en
Publication of WO2010023207A2 publication Critical patent/WO2010023207A2/en
Publication of WO2010023207A3 publication Critical patent/WO2010023207A3/en
Anticipated expiration legal-status Critical
Priority to IL211441A priority patent/IL211441A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • protein refers synonymously to the term "polypeptide”.
  • protein refers to a linear polymer of amino acid residues linked by peptide bonds in a specific sequence.
  • the amino-acid residues of a protein may be modified by e.g. covalent attachments of various groups such as carbohydrates and phosphate.
  • Other substances may be more loosely associated with the polypeptide chains, such as heme or lipid, giving rise to the conjugated proteins which are also comprised by the term “protein” as used herein.
  • proteins There are various ways in which the polypeptide chains fold have been elucidated, in particular with regard to the presence of alpha helices and beta-pleated sheets.
  • protein refers to all four classes of proteins being all-alpha, all-beta, alpha/beta and alpha plus beta.
  • the endolysin part is selected from the group consisting of phiKZgpl44 according to SEQ ID NO:1, ELgpl88 according to SEQ ID NO:2, Salmonella endolysin according to SEQ ID NO:3, Enterobacteria phage T4 endolysin according to SEQ ID NO:4, Acinetobacter baumanii endolysin according to SEQ ID NO:5, E.coli Phage KlF endolysin according to SEQ ID NO:6, OBPgpLYS according to SEQ ID NO: 7, PSP3 Salmonella endolysin (PSP3gplO) according to SEQ ID NO: 8 and E.coli Phage P2 endolysin (P2gpO9) according to SEQ ID NO: 9.
  • the endolysin variant comprises an endolysin and a peptide fused thereto said peptide comprising about 3 to about 50, more preferably about 5 to about 20, for instance about 5 to about 15 amino acid residues and at least 20, 30, 40, 50, 60 or 70%, more preferably at least 80%, for instance at least 90% of the said amino acid residues are either arginine or lysine residues.
  • the endolysin variant comprises an endolysin and a peptide fused thereto said peptide comprising about 3 to about 50, more preferably about 5 to about 20, for instance about 5 to about 15 amino acid residues and said amino acid residues are either arginine or lysine residues.
  • said disorder, disease or condition may be caused by Pseudomonas, in particular Pseudomonas aeruginosa and/or Pseudomonas putida, Burkholderia, in particular Burkholderia pseudomallei and/or Burkholderia solanacearum, Salmonella, in particular Salmonella typhimurium and/or Salmonella Enteritidis, Acinetobacter, in particular Acinetobacter baumannii, Escherichia coli and/or Klebsiella, in particular Klebsiella pneumoniae.
  • Pseudomonas in particular Pseudomonas aeruginosa and/or Pseudomonas putida
  • Burkholderia in particular Burkholderia pseudomallei and/or Burkholderia solanacearum
  • Salmonella in particular Salmonella typhimurium and/or Salmonella Enteritidis
  • Acinetobacter in particular Acinetobacter baum
  • the disorder, disease or condition is caused by Burkholderia pseudomallei, in particular Whitmore's Disease, chronic pneumonia, septicemia, in particular wherein the patient has a traumatized skin lesion.
  • PCR product was cloned in the pEXP5CT/TOPO® expression vector (Invitrogen, Carlsbad, CA, USA) according to the protocol of the manufacturer.
  • Arginine triplets were incorporated besides lysine triplets to avoid tRNA depletion and reduce the risk of frameshifts (the only two available triplets for lysine are AAA and AAG, leading to long A-stretches).
  • Insertion of additional polycationic cassettes into the designed BamHI restriction site lengthens the tail with extra cationic residues. This insertion creates an arginine and serine triplet at each junction site ( Figure 1).
  • pET32b The different products were cloned in the pET32b expression vector (Novagen, Darmstadt, Germany). pET32b was used to reduce potential toxicity of the polycationic peptide against the E. coli host.
  • a vector-encoded fusion protein (thioredoxin) masks the polycationic peptide and can be eliminated during the purification process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/EP2009/060947 2008-08-26 2009-08-25 Antimicrobial agents Ceased WO2010023207A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US13/061,053 US9809808B2 (en) 2008-08-26 2009-08-25 Antimicrobial agents
DK09782176.3T DK2331687T3 (da) 2008-08-26 2009-08-25 Antimikrobielle midler
PL09782176T PL2331687T3 (pl) 2008-08-26 2009-08-25 Środki przeciwdrobnoustrojowe
JP2011524360A JP5153943B2 (ja) 2008-08-26 2009-08-25 抗微生物剤
AU2009286760A AU2009286760B2 (en) 2008-08-26 2009-08-25 Antimicrobial agents
MX2011001957A MX2011001957A (es) 2008-08-26 2009-08-25 Agentes antimicrobianos.
CN200980142373.XA CN102197132B (zh) 2008-08-26 2009-08-25 抗微生物剂
CA2735077A CA2735077C (en) 2008-08-26 2009-08-25 Antimicrobial agents
ES09782176T ES2395357T3 (es) 2008-08-26 2009-08-25 Agentes antimicrobianos
EA201100312A EA024794B1 (ru) 2008-08-26 2009-08-25 Вариант эндолизина со встроенным катионным пептидом с активностью, разрушающей липополисахарид
KR1020117006983A KR101473271B1 (ko) 2008-08-26 2009-08-25 항균제
EP09782176A EP2331687B1 (en) 2008-08-26 2009-08-25 Antimicrobial agents
BRPI0917508-3A BRPI0917508A2 (pt) 2008-08-26 2009-08-25 Agentes antimicrobianos
HK11112268.7A HK1157818B (en) 2008-08-26 2009-08-25 Antimicrobial agents
IL211441A IL211441A (en) 2008-08-26 2011-02-27 Variety of endolysin, methods of manufacture and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0815484.1A GB0815484D0 (en) 2008-08-26 2008-08-26 Antibacterial agents
GB0815484.1 2008-08-26

Publications (2)

Publication Number Publication Date
WO2010023207A2 true WO2010023207A2 (en) 2010-03-04
WO2010023207A3 WO2010023207A3 (en) 2010-07-15

Family

ID=39846783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/060947 Ceased WO2010023207A2 (en) 2008-08-26 2009-08-25 Antimicrobial agents

Country Status (16)

Country Link
US (1) US9809808B2 (cg-RX-API-DMAC7.html)
EP (1) EP2331687B1 (cg-RX-API-DMAC7.html)
JP (2) JP5153943B2 (cg-RX-API-DMAC7.html)
KR (1) KR101473271B1 (cg-RX-API-DMAC7.html)
CN (1) CN102197132B (cg-RX-API-DMAC7.html)
AU (1) AU2009286760B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917508A2 (cg-RX-API-DMAC7.html)
CA (1) CA2735077C (cg-RX-API-DMAC7.html)
DK (1) DK2331687T3 (cg-RX-API-DMAC7.html)
EA (1) EA024794B1 (cg-RX-API-DMAC7.html)
ES (1) ES2395357T3 (cg-RX-API-DMAC7.html)
GB (1) GB0815484D0 (cg-RX-API-DMAC7.html)
IL (1) IL211441A (cg-RX-API-DMAC7.html)
MX (1) MX2011001957A (cg-RX-API-DMAC7.html)
PL (1) PL2331687T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010023207A2 (cg-RX-API-DMAC7.html)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149795A1 (en) * 2009-06-26 2010-12-29 Lysando Holding Establishment Antimicrobial agents
WO2011023702A1 (en) * 2009-08-24 2011-03-03 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin obpgplys
WO2011134998A1 (en) * 2010-04-27 2011-11-03 Lysando Holding Ag Method of reducing biofilms
WO2012059545A1 (en) 2010-11-03 2012-05-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Novel endolysin
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
CN103732235A (zh) * 2010-09-17 2014-04-16 药物技术业制药技术股份有限公司 抗菌噬菌体、噬菌体肽及其使用方法
US20140120074A1 (en) * 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
US8906365B2 (en) 2009-06-26 2014-12-09 Lysando Ag Antimicrobial agents
US9809808B2 (en) 2008-08-26 2017-11-07 Katholieke Universiteit Leuven K.U. Leuven R&D Antimicrobial agents
WO2018109229A1 (en) * 2016-12-16 2018-06-21 Universidade Do Minho Novel endolysin
WO2018185634A1 (en) * 2017-04-03 2018-10-11 Sasinapas Co., Ltd. Engineered gram-negative endolysins
US10167462B2 (en) 2013-11-14 2019-01-01 Lysando Ag Modified EL188 endolysin sequence
US10184120B2 (en) 2013-11-14 2019-01-22 Lysando Ag Modified KZ144 endolysin sequence
US10329550B2 (en) 2014-02-14 2019-06-25 Lysando Ag Antimicrobial agents
WO2019229185A1 (en) 2018-05-30 2019-12-05 Lysando Ag Novel antimicrobial proteins
WO2019229184A1 (en) 2018-05-30 2019-12-05 Lysando Ag Novel antimicrobial fusion proteins
US11180744B2 (en) 2014-06-26 2021-11-23 The Rockefeller University Acinetobacter lysins
EP3723789A4 (en) * 2017-12-12 2021-12-01 Contrafect Corporation LYSINES AND THEIR BACTERICIDAL DERIVATIVES AGAINST PSEUDOMONAS AERUGINOSA, IN THE PRESENCE OF HUMAN SERUM

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108578685A (zh) * 2011-04-21 2018-09-28 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
US9068204B2 (en) 2013-03-15 2015-06-30 The United States Of America, As Represented By The Secretary Of Agriculture Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation
AU2015243359B2 (en) * 2014-04-08 2020-03-12 Lysando Ag Pharmaceutical composition against chronic bacterial infections
CN104762285B (zh) * 2015-04-23 2017-10-27 武汉菲吉乐科生物科技有限公司 一种自内裂解大肠杆菌的裂解酶及其应用
AU2020268752B2 (en) * 2019-05-08 2025-12-18 BioNTech SE Novel gardnerella endolysins and uses thereof
WO2023225518A2 (en) * 2022-05-16 2023-11-23 The Broad Institute, Inc. Engineered pnma proteins and delivery systems thereof
CN117737001B (zh) * 2022-12-27 2024-08-09 菲吉乐科(南京)生物科技有限公司 一种防治犬细菌性腹泻的大肠杆菌噬菌体及其应用
CN118620800B (zh) * 2024-08-08 2024-11-12 中国兽医药品监察所 一株鼻疽伯克霍尔德氏菌及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854476T2 (de) 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
GB2255561B (en) * 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
EP0656952B1 (en) * 1992-08-21 2003-03-05 The University Of British Columbia Cationic peptides and method for production
PT778733E (pt) 1994-09-01 2001-06-29 Novozymes As Composicao proteica basica para matar ou inibir celulas microbianas
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US5997862A (en) * 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US5993809A (en) 1998-11-18 1999-11-30 Children's Hospital Medical Center Lysozyme fusion proteins in infections
AU5553600A (en) 1999-06-23 2001-01-31 Ppl Therapeutics (Scotland) Ltd Fusion proteins incorporating lysozyme
KR20050016362A (ko) 2002-04-22 2005-02-21 다우 글로벌 테크놀로지스 인크. 펩티드의 저비용 생산
US7566447B2 (en) 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
CA2536782A1 (en) 2003-09-11 2005-03-17 Novozymes A/S Recombinant production of antimicrobial agents
WO2005108563A2 (en) 2004-04-19 2005-11-17 University Of Chicago Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4
US7572602B1 (en) 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
EP2004215B1 (en) 2006-03-31 2010-06-09 The University Court of the University of St. Andrews Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase
DE102006061002A1 (de) * 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
EP3327030B1 (en) 2007-09-25 2021-07-21 Pastoral Greenhouse Gas Research LTD Vaccines and vaccine components for inhibition of microbial cells
US20100310522A1 (en) 2007-11-26 2010-12-09 Plant Bioscience Limited Novel Polypeptides Having Endolysin Activity and Uses Thereof
EP2318531A4 (en) 2008-07-24 2011-11-09 Us Agriculture TO RESISTANCE DEVELOPMENT REFRACTORY ANTIMICROBIAL ACTIVE SUBSTANCES
EP2157100A1 (en) 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
WO2010091294A2 (en) 2009-02-05 2010-08-12 The Regents Of The University Of California New targeted antimicrobial moieties
EP3714895A3 (en) 2009-06-26 2020-11-25 Lysando AG Antimicrobial agents
EA024253B1 (ru) 2009-08-24 2016-08-31 Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д Литический полипептид с пептидогликангидролазной активностью и его применение против инфекций, вызванных грамотрицательными бактериями
DK2563916T3 (en) 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809808B2 (en) 2008-08-26 2017-11-07 Katholieke Universiteit Leuven K.U. Leuven R&D Antimicrobial agents
US10137175B2 (en) 2009-06-26 2018-11-27 Lysando Ag Antimicrobial agents
EP3363896A1 (en) * 2009-06-26 2018-08-22 Lysando AG Antimicrobial agents
US11136570B2 (en) 2009-06-26 2021-10-05 Lysando Ag Antimicrobial fusion proteins comprising an endolysin and an amphipathic peptide segment
EA038542B1 (ru) * 2009-06-26 2021-09-13 Лисандо Аг Слитые белки для лечения инфекций, вызванных грамположительными бактериями
US8906365B2 (en) 2009-06-26 2014-12-09 Lysando Ag Antimicrobial agents
US11052137B2 (en) 2009-06-26 2021-07-06 Lysando Ag Antimicrobial agents
WO2010149795A1 (en) * 2009-06-26 2010-12-29 Lysando Holding Establishment Antimicrobial agents
EA024253B1 (ru) * 2009-08-24 2016-08-31 Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д Литический полипептид с пептидогликангидролазной активностью и его применение против инфекций, вызванных грамотрицательными бактериями
WO2011023702A1 (en) * 2009-08-24 2011-03-03 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin obpgplys
AU2010288559B2 (en) * 2009-08-24 2015-08-06 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin OBPgpLYS
CN102575240B (zh) * 2009-08-24 2016-01-13 勒芬天主教大学，K.U.勒芬R&D 新的细胞内溶素OBPgpLYS
US9169472B2 (en) 2009-08-24 2015-10-27 Lysando Ag Endolysin OBPgpLYS
AU2010288559A8 (en) * 2009-08-24 2015-08-13 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin OBPgpLYS
CN102575240A (zh) * 2009-08-24 2012-07-11 勒芬天主教大学，K.U.勒芬R&D 新的细胞内溶素OBPgpLYS
US8846865B2 (en) 2009-08-24 2014-09-30 Lysando Ag Endolysin OBPgpLYS
US9534223B2 (en) 2010-04-27 2017-01-03 Lysando Ag Method of reducing biofilms
CN103119158B (zh) * 2010-04-27 2015-04-08 莱桑多公司 减少生物膜的方法
CN103119158A (zh) * 2010-04-27 2013-05-22 莱桑多公司 减少生物膜的方法
WO2011134998A1 (en) * 2010-04-27 2011-11-03 Lysando Holding Ag Method of reducing biofilms
AU2011247584B2 (en) * 2010-04-27 2016-01-14 Lysando Ag Method of reducing biofilms
US10485854B2 (en) 2010-04-27 2019-11-26 Lysando Ag Method of reducing biofilms
JP2013532955A (ja) * 2010-04-27 2013-08-22 リサンド アクチェンゲゼルシャフト バイオフィルムの低減方法
EA037276B1 (ru) * 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
JP2016208985A (ja) * 2010-04-27 2016-12-15 リサンド アクチェンゲゼルシャフト バイオフィルムの低減方法
CN103732235A (zh) * 2010-09-17 2014-04-16 药物技术业制药技术股份有限公司 抗菌噬菌体、噬菌体肽及其使用方法
US9737579B2 (en) 2010-09-17 2017-08-22 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibacterial phage, phage peptides and methods of use thereof
US9399049B2 (en) 2010-09-17 2016-07-26 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibacterial phage, phage peptides and methods of use thereof
CN103201381A (zh) * 2010-11-03 2013-07-10 勒芬天主教大学，K.U.勒芬R&D 新的细胞内溶素
WO2012059545A1 (en) 2010-11-03 2012-05-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Novel endolysin
AU2011347152B2 (en) * 2010-12-23 2016-08-04 Katholieke Universiteit Leuven Antimicrobial agents
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
CN103403153A (zh) * 2010-12-23 2013-11-20 莱桑多公司 抗微生物制剂
WO2012085259A3 (en) * 2010-12-23 2012-08-30 Lysando Holding Ag Antimicrobial agents
US20140120074A1 (en) * 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
US10167462B2 (en) 2013-11-14 2019-01-01 Lysando Ag Modified EL188 endolysin sequence
US10184120B2 (en) 2013-11-14 2019-01-22 Lysando Ag Modified KZ144 endolysin sequence
US10329550B2 (en) 2014-02-14 2019-06-25 Lysando Ag Antimicrobial agents
US11180744B2 (en) 2014-06-26 2021-11-23 The Rockefeller University Acinetobacter lysins
AU2017375050B2 (en) * 2016-12-16 2021-07-22 Universidade Do Minho Novel endolysin
CN110300760A (zh) * 2016-12-16 2019-10-01 米尼奥大学 新的内溶素
WO2018109229A1 (en) * 2016-12-16 2018-06-21 Universidade Do Minho Novel endolysin
CN110300760B (zh) * 2016-12-16 2023-10-20 米尼奥大学 新的内溶素
WO2018185634A1 (en) * 2017-04-03 2018-10-11 Sasinapas Co., Ltd. Engineered gram-negative endolysins
US11208643B2 (en) 2017-04-03 2021-12-28 Sasinapas Co., Ltd. Engineered gram-negative endolysins
EP3723789A4 (en) * 2017-12-12 2021-12-01 Contrafect Corporation LYSINES AND THEIR BACTERICIDAL DERIVATIVES AGAINST PSEUDOMONAS AERUGINOSA, IN THE PRESENCE OF HUMAN SERUM
US12121568B2 (en) 2017-12-12 2024-10-22 Aurobac Therapeutics Sas Identification of lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa
WO2019229184A1 (en) 2018-05-30 2019-12-05 Lysando Ag Novel antimicrobial fusion proteins
WO2019229185A1 (en) 2018-05-30 2019-12-05 Lysando Ag Novel antimicrobial proteins
US11958890B2 (en) 2018-05-30 2024-04-16 Lysando Ag Antimicrobial proteins

Also Published As

Publication number Publication date
CA2735077A1 (en) 2010-03-04
HK1157818A1 (en) 2012-07-06
EA024794B1 (ru) 2016-10-31
ES2395357T3 (es) 2013-02-12
US20110243915A1 (en) 2011-10-06
AU2009286760B2 (en) 2015-08-27
CN102197132B (zh) 2016-01-13
CN102197132A (zh) 2011-09-21
JP2013081465A (ja) 2013-05-09
MX2011001957A (es) 2011-06-20
JP2012500642A (ja) 2012-01-12
BRPI0917508A2 (pt) 2015-08-04
JP5153943B2 (ja) 2013-02-27
DK2331687T3 (da) 2013-01-07
EP2331687A2 (en) 2011-06-15
KR20110049883A (ko) 2011-05-12
GB0815484D0 (en) 2008-10-01
JP5571757B2 (ja) 2014-08-13
PL2331687T3 (pl) 2013-02-28
US9809808B2 (en) 2017-11-07
WO2010023207A3 (en) 2010-07-15
AU2009286760A1 (en) 2010-03-04
EP2331687B1 (en) 2012-09-19
EA201100312A1 (ru) 2011-10-31
IL211441A (en) 2015-04-30
KR101473271B1 (ko) 2014-12-16
CA2735077C (en) 2019-04-09

Similar Documents

Publication Publication Date Title
AU2009286760B2 (en) Antimicrobial agents
AU2018201931B2 (en) Antimicrobial Agents
AU2011247584B2 (en) Method of reducing biofilms
HK1157818B (en) Antimicrobial agents
HK1224571B (en) Antimicrobial agents
HK1183687B (en) Method of reducing biofilms
HK1169311B (en) Antimicrobial agents
HK1224571A (en) Antimicrobial agents
HK1224571A1 (en) Antimicrobial agents
HK1172056A (en) New endolysin obpgplys

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980142373.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09782176

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009286760

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/001957

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2735077

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009286760

Country of ref document: AU

Date of ref document: 20090825

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011524360

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 211441

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201100312

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2009782176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 575/MUMNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117006983

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13061053

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0917508

Country of ref document: BR

Free format text: -COM BASE NA RESOLUCAO 228/09, SOLICITA-SE A APRESENTACAO DA DECLARACAO IMPRESSA E ASSINADA

ENP Entry into the national phase

Ref document number: PI0917508

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110221